Don’t Count Novavax’s Covid-19 Vaccine Out Just Yet

Skip to comments.
Don’t Count Novavax’s Covid-19 Vaccine Out Just YetNASDAQ ^
| 05/27/2021
Posted on 05/29/2021 9:11:39 PM PDT by SeekAndFind
Novavax (NASDAQ: NVAX) stock lost almost a third of its value over the past month driven by the companys announcement that it would delay seeking Emergency Use Authorization of its Covid-19 shot in the U.S., U.K., and Europe to the end of September, falling behind its initial plan of filing by June. This means that Novavax will probably miss out on lucrative…

Click here to view the original article.